Previous 10 | Next 10 |
A lot of small biotechs are fantastic buys right now. With Big Pharma sitting on a lot of cash, we might start seeing some smart acquisitions later this year. We asked a trio of contributors to pick the biotechs they're feeling most bullish about as potential buyout candidates in 2022. ...
Blueprint Medicines Corporation (BPMC) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland - Chief Executive Officer Christy Rossi - Chief Operating Officer Philina Lee - Chief Commercial Offic...
Blueprint Medicines press release (NASDAQ:BPMC): Q1 GAAP EPS of -$1.79 beats by $0.10. Revenue of $62.73M (+190.7% Y/Y) beats by $22.75M. For further details see: Blueprint Medicines GAAP EPS of -$1.79 beats by $0.10, revenue of $62.73M beats by $22.75M
Blueprint Medicines Reports First Quarter 2022 Results PR Newswire -- Achieved $23.8 million in AYVAKIT ® (avapritinib) net product revenues, and $62.7 million in total revenues -- -- AYVAKYT® (avapritinib) launch in Germany underway f...
Blueprint Medicines (NASDAQ:BPMC) is scheduled to announce Q1 earnings results on Tuesday, May 3rd, before market open. The consensus EPS Estimate is -$1.85 (-7.6% Y/Y) and the consensus Revenue Estimate is $39.98M (+85.3% Y/Y). Over the last 1 year, BPMC has beaten EPS estimates 50% of...
Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022 PR Newswire CAMBRIDGE, Mass. , April 26, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conferenc...
Investing in biotechnology companies is both difficult and incredibly exciting. Watching as a company goes through the regulatory approval process, from a fledgling early-stage clinical trial biotech to an industry juggernaut, can be exhilarating. While positive outcomes aren't guarante...
Blueprint Medicines (NASDAQ:BPMC) on Friday announced a clinical trial supply agreement with AstraZeneca (AZN) under which it will evaluate its investigational agents BLU-945 and BLU-701 in combination with osimertinib in its ongoing SYMPHONY and HARMONY trials, respectively. Blueprint also a...
Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in EGFR-mutant Non-Small Cell Lung Cancer PR Newswire -- Early dose escalation data show dose-dependent reductions in ctDNA and tumor bur...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Blueprint Medicines (NASDAQ: BPMC ): initial data from a Phase 1/2 study of a lung cancer drug candidate for patients with certain types of mutation Bristol-Myers Squibb (NYSE: BMY ): Food and Drug Admi...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 30.3% to $0.2932 on volume of 173,918,707 shares Emergent Biosolutions Inc. (EBS) rose 71.0% to $3.3 on volume of 150,987,238 shares PROSHARES TRUST (SQQQ) fell 3.6% to $11.78 on volume of 136,332,744 sh...
U.S. stocks were higher, with the Dow Jones index gaining over 50 points on Thursday. Shares of C.H. Robinson Worldwide, Inc. (NASDAQ:CHRW) rose sh...
A look at the top 10 most actives in the United States Allarity Therapeutics Inc. (ALLR) rose 97.8% to $2.71 on volume of 44,141,232 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 1.1% to $0.0456 on volume of 28,670,184 shares Emergent Biosolutions Inc. (EBS) rose 67.7% to $3...